Clinical Trial: Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
Study Status: Completed
Recruit Status: RECRUITING
Condition: Head and Neck Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase I Trial of Re-Irradiation With Concurrent Chemotherapy in Combination With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Squamous Cell Carcinoma
Brief Summary:
The purpose of this study is to evaluate the safety, tolerability and maximum tolerated dose of tislelizumab in combination with pamiparib plus chemoradiotherapy (chemotherapy and radiation) in individuals with recurrent head and neck cancer, which means that the person's cancer has come back after treatment.Participation in the study should last for about 15 months while participants receive tislelizumab and chemoradiotherapy with pamiparib.Afterwards, they will return to the clinic for follow up every 4…
Read more